With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short

Dizal Pharmaceutical’s Zegfrovy is now FDA approved for treating non-small cell lung cancer driven by a particular rare genetic signature. Johnson & Johnson drug Rybrevant already addresses this genetic signature as an earlier line of therapy, but Dizal executives contend their drug offers the potential for better safety and efficacy. The post With FDA Nod…

Read More

CDC Firings Undermine Public Health Work Far Beyond Washington

The Trump administration’s sudden firing of Centers for Disease Control and Prevention employees gutted training programs across the nation whose participants bolstered the workforce of state and local public health departments that for decades have been starved of resources. The programs are designed to cultivate a new generation of public health leaders, many of whom…

Read More

Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs

December has seen a slew of executive hires, promotions and layoffs across the healthcare industry. For instance, Breyer Capital, the FDA and Strive Health named new executives. There were also layoffs at organizations including Alameda Health System, Pfizer and Voyager Therapeutics. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first…

Read More

Breaking Language Barriers in Healthcare Employee Communication with TeamTranslate™

Effective communication is the backbone of any successful operation, especially in environments as dynamic and diverse as healthcare. In hospitals across the country, language barriers have long been a challenge, impacting everything from day-to-day operations to patient care and satisfaction.    Breaking Down Language Barriers in Healthcare Employee Communication Enter Relay’s TeamTranslate™ feature—a groundbreaking technology designed…

Read More